Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Effect of Subacute Ibuprofen Dosing on Rectal Mucosal Prostaglandin E2 Levels in Healthy Subjects with a History of Resected Polyps

H-H. Sherry Chow, David L. Earnest, David Clark, Nancy Mason-Liddil, Cheryl B. Kramer, Janine G. Einspahr, Jose M. Guillen-Rodriguez, Denise J. Roe, Winfred Malone, James A. Crowell and David S. Alberts
H-H. Sherry Chow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David L. Earnest
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Clark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy Mason-Liddil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheryl B. Kramer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janine G. Einspahr
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose M. Guillen-Rodriguez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denise J. Roe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Winfred Malone
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James A. Crowell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David S. Alberts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2000
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Plot of the relationship between baseline rectal mucosal PGE2 content and BMI. The baseline rectal mucosal PGE2 content was an average of the data collected before and at the end of the run-in period. ——, a regression fit of the data (Y = 12.5 × X − 103.2; r2= 0.269; P = 0.007) without the inclusion of the data point in parentheses.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Plot of the rectal mucosal PGE2 content in each individual subject before and after placebo/ibuprofen treatment. ∗, the data after 4 weeks of ibuprofen treatment were not available.

Tables

  • Figures
  • Table 1

    Demographic data of the study participants

    PlaceboIbuprofen 300 mg/dayIbuprofen 600 mg/day
    No. of subjects999
    No. of present smokers111
    No. of females443
    Age (year)58 ± 13a59 ± 1062 ± 5
    (39–73)b(39–70)(54–69)
    Height (cm)167 ± 16171 ± 11172 ± 7
    (134–188)(161–190)(161–180)
    Weight (kg)88 ± 2887 ± 2483 ± 9
    (64–152)(58–121)(65–96)
    BMI (kg/m2)31.7 ± 8.229.6 ± 7.828.3 ± 3.9
    (23–49)(21–44)(20–31)
    • a Mean ± 1 SD.

    • b Data range.

  • Table 2

    Mean plasma ibuprofen levels (μg/ml) before and after daily ibuprofen treatment

    Ibuprofen dose (mg/day)Before the placebo run-in periodAt the end of the placebo run-in periodAfter 2 wk of ibuprofen treatmentAfter 4 wk of ibuprofen treatment
    0 (placebo)0 ± 00 ± 00 ± 00 ± 0
    3000 ± 00 ± 012.7 ± 4.513.3 ± 3.2
    6000.17 ± 0.52a0.20 ± 0.60a21.1 ± 6.1b26.3 ± 8.0b
    • a Resulted from ibuprofen levels seen in one individual.

    • b Significantly different from subjects taking 300 mg/day ibuprofen; P < 0.05.

  • Table 3

    Mean rectal mucosal PGE2 content (pg/mg protein) before and after ibuprofen treatment

    Ibuprofen dose (mg/day)Averaged baseline (before and at the end of the run-in period)After 2 wk of treatmentAfter 4 wk of treatment
    0 (placebo)394.7 ± 221.8257.4 ± 180.9178.2 ± 91.5
    300237.9 ± 128.6100.2 ± 91.598.6 ± 41.4
    600215.6 ± 123.8133.1 ± 123.9115.1 ± 160.8
  • Table 4

    The PGE2 levels after 2 or 4 weeks of ibuprofen/placebo treatment, expressed as percent of the baseline values (100 × ((PGE2)posttreatment/(PGE2)baseline))

    Ibuprofen dose (mg/day)After 2 wk of treatmentAfter 4 wk of treatment
    0 (placebo)78 ± 5269 ± 78
    30045 ± 30a51 ± 28
    60059 ± 2660 ± 46
    • a Changes in logarithmically transformed PGE2 levels were significantly different from those after placebo treatment (see data analysis section for details); P = 0.033.

PreviousNext
Back to top
April 2000
Volume 9, Issue 4
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Effect of Subacute Ibuprofen Dosing on Rectal Mucosal Prostaglandin E2 Levels in Healthy Subjects with a History of Resected Polyps
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effect of Subacute Ibuprofen Dosing on Rectal Mucosal Prostaglandin E2 Levels in Healthy Subjects with a History of Resected Polyps
H-H. Sherry Chow, David L. Earnest, David Clark, Nancy Mason-Liddil, Cheryl B. Kramer, Janine G. Einspahr, Jose M. Guillen-Rodriguez, Denise J. Roe, Winfred Malone, James A. Crowell and David S. Alberts
Cancer Epidemiol Biomarkers Prev April 1 2000 (9) (4) 351-356;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Effect of Subacute Ibuprofen Dosing on Rectal Mucosal Prostaglandin E2 Levels in Healthy Subjects with a History of Resected Polyps
H-H. Sherry Chow, David L. Earnest, David Clark, Nancy Mason-Liddil, Cheryl B. Kramer, Janine G. Einspahr, Jose M. Guillen-Rodriguez, Denise J. Roe, Winfred Malone, James A. Crowell and David S. Alberts
Cancer Epidemiol Biomarkers Prev April 1 2000 (9) (4) 351-356;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Urinary Melatonin in Relation to Breast Cancer Risk
  • Endometrial Cancer and Ovarian Cancer Cross-Cancer GWAS
  • Risk Factors of Subsequent CNS Tumor after Pediatric Cancer
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement